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Abstract 
The present study investigated the genoprotective and genotoxic effects of 
myricetin bulk (10 µМ) and nano forms (20 µМ) in the lymphocytes from pre-
cancerous, monoclonal gammopathy of unknown significance (MGUS) patients 
and healthy individuals using the Comet and micronucleus assays.  The study 
also evaluated the effect of myricetin on P53 expression levels, using the 
Western blot technique. Results showed that throughout the in-vitro treatment, 
lymphocytes from the patients group had higher levels of basel ine DNA 
damage compared to the healthy group. Myricetin in both forms induced 
significant DNA damage, only at higher concentrations (>40 µМ). The 
micronucleus assay showed a significant reduction (P<0.01) in the frequency of 
micronuclei in mono-nucleated cells in the patient group treated with the nano 
form of myricetin at the non-toxic dose of 20 µМ. There was a significant 
increase in both gene and protein P53 levels in lymphocytes isolated from 
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healthy individuals and pre-cancerous patients. These results suggested a 
protective effect of myricetin and indicated its nutritional supplement potential 
for protection against cancer development among patients suffering from 
MGUS. 
Keywords: myricetin, bulk and nano forms; lymphocytes; pre-cancerous 
patients; healthy individuals; genoprotective; P53; ATM; Comet and 
micronucleus assays 
Introduction  
Myricetin belongs to the family of flavonoids; flavonols, with antioxidant 
properties. The three hydroxyl groups in ring B (3′,4′,5′-position) (Figure 1) make 
it a stronger antioxidant and anti-carcinogen by scavenging reactive oxygen 
species (ROS) through oxidation of these hydroxyl groups (Li and Ding, 2012), 
via interactions with various enzymes and receptors involved in signal 
transduction and by inhibiting protein kinases (PKs), such as cyclin dependent 
kinases (CDKs) causing cell cycle arrest (Batra and Sharma, 2013). Myricetin is 
usually contributed by vegetables, berries, tea, fruits, nuts and red wine to our 
diet (Ross and Kasum, 2002; Büchter et al., 2013).  Its average intake varies, 
subject to the diet consumed and lifestyle factors. Myricetin is made from the 
parental compound taxifolin through an intermediate, dihydromyricetin and can 
also be directly produced from kaempferal (Flamini et al., 2013). Myricetin 
exhibits many health benefits including, anti-oxidant, anti-photo aging, anti-
cancer, anti-hypertension, anti-inflammatory, anti-allergic, anti-microbial, anti-
diabetic, immunomodulatory, analgesic and protective effects against 




Figure 1. Chemical structure of myricetin  
Maintaining homeostasis between the damage and repair mechanisms is 
crucial for the integrity of our genome. For this an eukaryotic cell bears a highly 
specialised system called ‘cell cycle checkpoints’ that keeps check on every 
step of the cell cycle and guarantees a healthy and smooth progression 
(Hartwell and Weinert, 1989; Ciccia and Elledge, 2010).The tumour suppressor 
protein, P53, is the key regulator of the cell cycle and is considered as the main 
mediator of checkpoint triggered arrest in G1 phase and its function is critical for 
defence against cancer development. Various cellular stress signals including 
hypoxia, DNA damage, nucleotide deprivation, different infections and oxidative 
stress etc. can lead to the initiation of P53 transcription (Cox and Lane, 1995) 
and therefore P53 can be a leading factor in tumour progression. 
MGUS is a condition where a small number of plasma cells start producing 
paraprotein (not able to fight infection with its presence as an initial and 
important sign of myeloma and paraprotein can be detected either in urine or 
serum) but still with no appearance of myeloma at that stage. People who suffer 
from MGUS are at higher prevalence of multiple myeloma at an average rate of 




Although past studies have demonstrated some of the characteristics of 
myricetin against different diseases, this is t h e  first study that investigated the 
effects of myricetin at a particle size at the cellular level ex vivo/in vitro. In the 
present study, DNA damage in peripheral lymphocytes of pre-cancerous 
patients with MGUS and healthy individuals have been compared after 
treatment with nanoparticle (MYR N) and bulk (MYR B) forms of  my r ic e t i n  
a t  b as e l i n e  l e v e ls  in the Comet and micronucleus assays. As we only 
used human subjects for our study, the heterogeneity of the population was b 
matched as well as possible and the effects of the confounding factors were 
determined. Lymphocytes were used as a cell model because lymphocytes are 
considered as standard surrogate cells for human monitoring studies due to 
their excellent features including capacity to retain genetic defects for longer 
compared to other cell types (Anderson et al,. 2014). This study also 
investigated the effects of MYR B and MYR N on protein and gene expression 
levels of the tumour suppressor gene P53 using Western blot and real-time 
PCR techniques, respectively. 
Materials and methods  
Blood sample collection and Ethics 
The current project involving the use of human peripheral lymphocytes was 
granted ethical approval by Leeds East Ethics Committee (Reference 
No.:12/YH/0464) and the University of Bradford’s Sub-Committee for Ethics in 
Research involving healthy Human Subjects (Reference No.: 0405/8). All 
peripheral blood samples were collected after informed consent from patients 
and healthy individuals. The research support and governance office of 
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Bradford Teaching Hospitals NHS Foundation also approved and agreed the 
research (REDA number 1202). 
The blood samples from healthy individuals and pre-cancerous patients used in 
the current study are listed below in Tables 1 and 2, respectively. The exclusion 
criterion for human subjects enrolled in the study was individuals with anaemia, 
blood diseases or major disorders. However, the inclusion criterion for patients’ 
group was individuals with MGUS. 
Blood samples were diluted 1:1 with RPMI-1640 medium (Invitrogen, UK) and 
supplemented with 10% dimethyl sulphoxide (DMSO) (Invitrogen, UK). Then 
these were aliquoted and immediately stored at -800C to be used in the Comet 
assay. Past studies have confirmed that frozen blood can be used instead of 
fresh blood for the Comet assay and there is no significant difference for DNA 
damage between both frozen and the fresh samples (Hininger et al., 2004; Milić 
et al., 2019; Bøhn et al., 2019). However, for all other techniques freshly 
obtained blood was utilised as per the requirement for each procedure. 




1 48 CAUCASIAN M NO NONE 
2 28 CAUCASIAN M NO NONE 
3 27 AFRICAN M YES NONE 
4 38 CAUCASIAN M NO NONE 
5 60 CAUCASIAN F NO NONE 
6 40 ARAB M NO NONE 
7 45 CAUCASIAN M YES  NONE 
8 55 CAUCASIAN M NO NONE 
9 35 CAUCASIAN M YES NONE 
10 25 CAUCASIAN M NO NONE 
11 44 ASIAN M YES NONE 
12 28 CAUCASIAN M NO NONE 
13 23 CAUCASIAN F NO NONE 
14 27 CAUCASIAN M NO KIDNEY 
CANCER 
15 33 ARAB M YES NONE 
16 47 ASIAN M YES NONE 
17 28 CAUCASIAN M NO NONE 
18 42 ASIAN M NO NONE 
19 48 ASIAN M NO NONE 
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20 60 ASIAN M YES NONE 
 
Table 1. Healthy blood samples (M=male, F=female) 




Family history Medical condition 
1 79 CAUCASIAN M NO NONE MGUS,COPD,MBCL 
2 80 CAUCASIAN F NO NONE- MGUS 
3 78 CAUCASIAN M NO NONE- MGUS 
4 56 CAUCASIAN F YES LEUKAEMIA & 
BRAIN TUMOUR 
MGUS 
5 77 CAUCASIAN M NO NONE MGUS 
6 75 CAUCASIAN M NO NONE MGUS 
7 80 CAUCASIAN M NO CANCER POSITIVE MGUS 
8 81 CAUCASIAN F NO BOWEL&STOMACH MGUS 
9 63 CAUCASIAN M YES NONE MGUS 
10 55 CAUCASIAN M NO NONE MGUS 
11 83 CAUCASIAN M NO NONE MGUS, BPR 
12 63 CAUCASIAN M YES NONE MGUS 
13 74 CAUCASIAN M NO NONE MGUS COPD 
14 63 CAUCASIAN F YES ARTHRITIS MGUS, COPD 
15 66 CAUCASIAN F NO BREAST CANCER MGUS 
16 52 CAUCASIAN M YES NONE MGUS 
17 83 CAUCASIAN M NO NONE MGUS 
18 60 ASIAN F NO NONE MGUS 
19 75 CAUCASIAN F NO MASTECTOMY MGUS 
20 69 CAUCASIAN M NO STOMACH  cancer MGUS 
 
Table 2. Brief information about pre-cancerous patient’s samples  
Key for Tables 1 and 2: (M=male, F=female, MGUS=monoclonal gammopathy of unknown 
significance, COPD=chronic obstructive pulmonary disease, MBCL= Monoclonal B cell 
lymphocytosis, BPR= Benign prostatic hyperplasia) 
Preparation of myricetin bulk and nano forms, concentration, solubility 
and zeta potential of nanoparticles 
Myricetin was purchased from Fisher Scientific, UK, as a powder (˃96% purity). 
Preparation of myricetin bulk and nano suspensions and dose response curve 
can be found in our previous study (Akhtar et al,. 2020). The concentrations 
used for myricetin bulk and nano forms were 10 and 20 µM, respectively and 
gave equi-toxic survival responses. The mean particle sizes of myricetin nano in 
the stock solutions were measured using a Zetasizer Nano ZS-90 Model 
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ZEN3600 (Malvern Instruments Ltd, UK) by Photon Correlation Spectroscopy. 
The stability of the particles for both forms of myricetin was assessed every 
month by checking their particle size and the difference were less than 1%. 
Hence, these were considered stable enough to be used for the study. The 
suspensions were also sonicated for 10 mins before each use to avoid 
sedimentation and control aggregation. 
Isolation of lymphocytes 
Whole heparinised blood was diluted with 0.9% saline (1:1 dilution) and mixed 
thoroughly. Diluted blood was then layered on top of lymphoprep (Invitrogen, 
UK) layer and centrifuged for 20 mins to isolate the lymphocyte pellet which was 
then carefully separated, and cells were cultured in RPMI-1640 (Sigma Aldrich, 
UK) medium overnight at 37 0C in the presence of CO2. 
MTT assay 
The cytotoxicity of chemicals was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) dye absorbance. Isolated lymphocytes 
(104) were maintained in complete medium [RPMI 1640 without phenol red, 1 % 
penicillin-streptomycin and 15 % foetal bovine serum (FBS)] overnight in 96-well 
plates and treated with the desired chemicals. Then the MTT dye (Fisher 
Scientific, UK) (5 mg/ml) was added to each well and incubated for 4 hours at 
370C in the dark. After this, 200 µl DMSO (Fisher Scientific, UK) was added to 
each treatment and absorbance was read at 570 nm. The experiment was 
repeated 3 times in each investigative group.  
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DNA damage determination using the Comet assay 
Materials: RPMI medium (Invitrogen, UK),0.5 % low melting point (LMP) 
agarose and 1 % normal melting point agarose (NMP)(Invitrogen, UK), 10 % 
dimethyl sulphoxide (DMSO) (Sigma Aldrich, UK), ethidium bromide (EB) 
(Sigma, UK), frozen blood samples. 
Procedure: A total of 100 µl suspension of thawed blood sample, 10 µl of the 
chemical and 890 µl of RPMI medium were added simultaneously making a 
total treatment volume of 1000 µl in separate Eppendorf tubes for each 
treatment groups (positive control (PC) H2O2 50 µМ; MYR B 10 µМ and MYR N 
20 µМ). And incubated for 30 mins at 37 0C. For the untreated negative control, 
only blood suspension was added in RPMI medium. The procedure was 
performed as described previously (Tice et al, 2000; OECD, Test No. 489; 
Anderson et al, 2014; Azqueta and Dusinska, 2015). For DNA staining, 60 µl of 
EB (20 µg/ml) was added to the slides. Slides from 20 healthy individuals and 
20 from the patient group were analysed using the two parameters of the Comet 
assay, % tail DNA and Olive tail moment (OTM) using Komet 6 software, Kinetic 
imaging (Andor Technology Ltd, Belfast, UK). A total of 100 cells were counted 
from duplicate slides per treatment group and mean with standard errors were 
used to analyse the data. 
Micronucleus (MN) assay 
Chemicals: Phytohaemagglutinin (PHA), RPMI 1640 with 25 mM HEPES and L-
Glutamine, penicillin-streptomycin and foetal bovine serum (FBS) (Invitrogen ltd, 
UK), cytochalasin B (cyt-B) (Sigma, UK) 
Cell culture: (all steps in sterile conditions): Fresh blood samples supplemented 
with PHA were added to conical flasks containing basic culture medium (RPMI 
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1640 with 25 mM HEPES and L-Glutamine), 1 % penicillin-streptomycin and 15 
% FBS and incubated for 24 hrs at 37 °C in the presence of 5 % CO2. After the 
incubation time was over, cell cultures were exposed to the desired chemical 
treatments. Mitomycin C (MMC) 0.4 µМ was used as the positive control. The 
assay procedure was followed as described by Fenech (OECD, Test No. 487; 
Fenech, 2007). To determine the frequency of MNi, nuclear division index 
(NDI), buds and bridges, 1000 cells were scored according to criteria 
characterized by Fenech (2007). The tests were repeated 5 times in each 
investigative group as a minimum standard number of experiments, which is 
considered scientifically acceptable (Dandah, 2018). 
Western blot analysis 
Lymphocytes were seeded in 6-well plates at concentration of 106 cells/well, 
incubated overnight and treated with chemicals for 24 hrs. Then the cells were 
washed twice with cold PBS and lysed by adding 150 µl lysis buffer 
supplemented with 15 µl of fresh protease inhibitor cocktail to the cells. Total 
protein levels were determined using the Bio-Rad Bradford assay kit (Bio-Rad, 
UK). The cell lysates were separated using protein electrophoresis and blotted 
on nitrocellulose membranes (Abcam, UK). The membranes were blocked 
overnight in 5 % bovine serum albumin (BSA) diluted in Tris-buffered saline 
supplemented with 0.1 % Tween 20 at 4 0C (All from Sigma Aldrich, UK). The 
membranes were then incubated with primary and secondary antibodies 
(Abcam, UK) dilutions, overnight at 4 0C and then for 1 hr at room temperature, 
respectively and visualized using the enhanced luminol-based 
chemiluminescent (ECL) system. Each experiment was repeated 3 times. 
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Real-time RT-PCR analysis 
Isolated lymphocytes were seeded in 6-well plates (106 cells/well) and treated 
with chemicals for 24 hrs. Two micrograms of total isolated RNA was subjected 
to reverse transcription using iScriptTM c DNA synthesis kit (Bio Rad, UK) 
according to the manufacturer protocol. Each Real-time PCR experiment was 
done three times in a total of 10 microliter reaction mixture. Primers (Sigma 
Aldrich, UK) used for PCR reactions are shown in Table 3. Data were analysed 
using the 2-DDCt method (Livak and Schmittgen, 2001) and normalised against 
the internal home gene Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
in each sample. 
Genes Primer Sequence 5’-3’ 
ATM   ACCATTGTAGAGGTCCTTC 








Table 3.Primers used for Real-Time PCR analysis 
Statistical analysis 
Graph Pad prism 7 was used to perform statistical calculations. The results 
were analysed using t-tests and one-way analysis of variance (ANOVA) to test 
differences between each treatment and control. A p-value of <0.05 was 
considered statistically significant. 
Results 
Particle size determination of myricetin bulk and nanoparticles 
Although, the particle size determined for myricetin nanoparticles (NPs) was 
˃100 nm, we still refer to them as NPs of myricetin. Nano particles of myricetin 
suspended in excipient mixture were compared to the solution prepared from its 
bulk powder in the same excipient mixture. Results showed the average particle 
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size of myricetin bulk and nanoparticles as 1737 and 161 nm respectively 
(Table 4). Nanoparticles of myricetin were much smaller compared to the bulk 
particles. Reduction in the size of nanoparticles provides a higher bioactivity 
and enhanced dissolution rate than the bulk form. This is because upon addition 
to the cell culture medium, nanoparticles are capable of providing higher 
concentrations of the drug in the immediate vicinity or inside the cells. 
Nanoparticles have been shown to penetrate cell membranes via phagocytosis 
and endocytosis and thus provide a higher effective dose within the cells 
(Gradinaru et al., 2010). It is reported that particles in the size range of 250 nm 
to 3 μm are mainly internalised by phagocytosis whereas those below 200 nm 
are mainly taken up by endocytosis (Amit et al., 2014). Nano medicine has been 
shown to exhibit different biological activity compared to solutions of the same 
drug. 





Myricetin nano +161.0 0.501 0.961 Good 
Myricetin bulk +1737 - - Good 
 
Table 4 .Average particle size of Myricetin bulk and NPs 
Cytotoxicity of myricetin bulk and nanoparticles in lymphocytes from 
healthy vs. patient groups 
The MTT assay was used to determine the cytotoxicity of myricetin. The results 
revealed a significant (P<0.01, P<0.003) time and concentration-dependent 
cytotoxicity which was measured at 570 nm by optical density. Figure 2 
demonstrated the effects of various treatment groups on the viability of healthy 
and pre-cancerous patients’ lymphocytes at different times (1, 24 and 48 hrs) 
compared to the respective untreated group where H2O2 significantly reduced 
the viability after 48 hrs. MYR B and MYR N also induced a time and 
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concentration dependent decrease in cell viability. MYR B (40 µМ) and MYR N 
(40 µМ) reduced the viability in lymphocytes to 88 % and 86 % from healthy 
individuals and to 86 % and 83 % from pre-cancerous patients respectively, 
after a 48 hrs treatment. Neither of the concentrations of MYR B and MYR N 
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Figure 2. Shows the % cell viability of lymphocytes from healthy volunteers (age, 50-60) 
(A) and from pre-cancerous patients (age, 50-60) (B), after treating the different treatment 
groups: NC (untreated cells), excipient mixture (EM)(0.1%), MYR B (10-40 µМ), MYR N (10-40 
µМ), PC (H2O2 50 µМ) for 1, 24 and 48 hours measured using the MTT assay. The percentage 
of cell survival was evaluated for various concentrations of the tested chemicals, while 
compared to the untreated group (NC). The values represent the mean of 3 separate 
experiments. (ns=not significant, *P<0.01, **P<0.003) 
Concentration dependent responses of myricetin bulk (MYR B) and 
myricetin nano (MYR N) to determine genotoxicity 
Since the MTT assay revealed the cytotoxicity caused by the various doses 
used was less than  25 %, genotoxicity was assessed using a range of 
concentrations (10 µМ to 80 µМ) of MYR B and MYR N. Flavonoid compounds 
have this ability to cause adverse effects at slightly different concentrations as 
evaluated in our previous study (Akhtar et al., 2020) where MYR N 20 µM has 
been shown safer than MYR N 10 µM, therefore; we used the safer 
concentrations 10 µM and 20 µM for MYR B and MYR N, respectively  with no 
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significant genotoxicity (Data shown in Akhtar et al., 2020). As we conducted an 
in vitro study, these chosen concentrations are safe and acceptable to use on 
lymphocytes knowing that in vivo the physiological concentration range of 
myricetin is from 5-10 µМ (Peng and Kuo, 2003). Compilation of various studies 
presented by Semwal (2016) has shown wide concentration ranges (10-100 
µМ) used for myricetin which are well above its physiological range and 
produced protective effects against different cancers and cardiovascular 
diseases. 
Confounding factors 
Confounding factors such as age, gender, ethnicity, lifestyle (diet, smoking and 
drinking habits) and environmental factors are very important and need to be 
considered when assessing the DNA damage in humans because these may 
contribute to DNA damage and therefore could induce genotoxicity (Fenech, 
2007). Lifestyle variables such as smoking and alcohol consumption may 
render individuals susceptible to cancer and other diseases because they are 
known carcinogens. Age could also contribute towards the DNA damage due to 
compromised immune system and DNA repair mechanism. Therefore, we 
determined the effects of these variables on the Comet values in both the 
healthy individuals and pre-cancerous patients.  In the present study, we found 
no relationship between any of the confounding factors and DNA damage in 
both groups, except for ethnicity in the patient group where Asian and 
Caucasian populations had significantly different effects (p<0.01) when treated 
with PC. However, these do not seem to be contributing much towards DNA 
damage overall as shown in results from healthy individuals which have little 
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basal damage. All patients were suffering from various diseases which were the 

















OTM OTM OTM OTM OT
M 




NC 1.10 0.70 0.7 0.71 1.23 0.81 2.73 4.12 
PC (H2O2 
50µМ) 8.90 10.70 11.81 8.90 8.12 13.50 6.72 10.31 
MYR B 
(10µМ) 2.01 1.49 1.11 2.01 1.50 1.33 3.17 6.02 
MYR N 





NC 3.63 2.80 4.01 2.55 2.24 2.61 3.50 3.24 
PC (H2O2 
50µМ) 9.01 8.70 
15.51
* 6.22* 6.40 5.43 9.50 11.92 
MYR B 
(10µМ) 2.53 3.40 6.91 3.86 2.62 3.30 3.91 4.50 
MYR N 
(20µМ) 2.30 1.75 4.00 2.90 1.00 1.82 2.11 3.13 
 
Table 5.The effect of Confounding factors 
Assessment of DNA damage using the Comet Assay 
The effects of myricetin nano and bulk forms on DNA damage of 
lymphocytes from healthy volunteers 
After treating lymphocytes from healthy individuals with MYR B (10 µМ) and 
MYR N (20 µМ) using the Comet assay, there were no significant effects 
observed in DNA damage when compared against the untreated control (Akhtar 
et al., 2020) 
Comparison between myricetin nano and bulk form responses on DNA of 
lymphocytes from pre-cancerous patients 
In vitro treatment of lymphocytes taken from pre-cancerous patients with MYR B 
(10 µМ) and MYR N (20 µМ) showed no significant difference from the control 
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group (Figure 3). Since both parameters of the Comet assay, OTM and % tail 












































Figure 3. The response of MYR B and MYR N, on lymphocytes from pre-cancerous 
patients using OTM. This graph shows the mean and standard errors of experiments on 20 
individuals (measuring 100 cells each) in which four treatment groups were tested for DNA 
damage in patient lymphocytes as follows: an untreated lymphocyte group (NC), excipient 
mixture (EM), positive control (PC) 50 µM H2O2, myricetin bulk (MYR B 10 µM) and myricetin 
nano (MYR N 20 µM).   All other groups were compared to the negative control. (***P< 0.001, ns 
= not significant). The mean negative control and positive control values for OTM were 2.8 and 
6.9, respectively. 
Determination of micronuclei (MNi) and other DNA damage 
 MNi frequency in MoNC 
Untreated cultures of the patient group showed higher numbers of MNi in MoNC 
by comparison with the healthy control group. This shows pre-existing 
chromosomal damage in the patient group might be present due to the disease 
state. Mitomycin C significantly induced MNi formation in both groups. MYR B 
has not shown any significant effect on MNi induction on either of the groups. 
However, MYR N has significantly reduced MNi formation in MoNC from pre-
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Figure 4 Shows, MNi frequency observed in MonoNC cells. Data are expressed as means 
standard error (SE). Treatment of lymphocytes with the positive control (Mitomycin C {0.4 µM 
MMC}), MYR B and MYR N, compared to the respective untreated groups. (***P< 0.001,* P< 
0.02 and **P< 0.006, ns = not significant). Horizontal lines with the statistics above them show 
the differences between the groups. The statistics below horizontal lines show the comparison 
of treatment groups with respective untreated group. 
Other determinants of MN 
The following Table (6) shows the other important biomarkers of damage 
assessed in the micronucleus assay. There is no significant difference between 
the NDI and BiNC percentage among all the treatment groups. EM did not 
cause any damage in healthy lymphocytes. MYR B and MYR N at selected non-
genotoxic concentrations did not induce any nuclear bridges or buds in both 
investigative groups. The number of MNi in BiNC from pre-cancerous patients 
(aged between 55 and 65) was higher than those from healthy individuals at 
basal levels (aged between 45 and 60). Overall there was a protective effect in 
the patients group but non-significant damage in healthy individuals. 
Subject Treatment 
Group 
NDI % BiNC Per 1000 BiNC CELLS 
BiMNi BiNPB BiBuds 
Healthy 
individuals 
NC 1.85 62 0 0 0 








EM 1.84 (ns) 60 (ns) 0 (ns) 0 (ns) 0 (ns) 
MYR B 1.82 (ns) 63 (ns) 2 (ns) 0 (ns) 0 (ns) 




NC 1.81 61 6 1 0 
0.4 µM MMC 1.85 (ns) 61 (ns) 18 (P<0.001) 4 (P<0.04) 2 
(P<0.05) 
EM 1.80 (ns) 62 (ns) 4 (ns) 0 (ns) 0 (ns) 
MYR B 1.8 (ns) 64 (ns) 5 (ns) 0 (ns) 0 (ns) 
MYR N 1.87 (ns) 62 (ns) 3 (ns) 0 (ns) 0 (ns) 
 
Table 6 The average mean ± SE of various markers of chromosomal damage in the 
micronucleus assay. Showing NDI per treatments on healthy and patient cells, mean % of 
BiNC, mean number of MNI, NPBs and NBUDS per 1000 BiNC. Five treatment groups included 
the negative control, a positive control group (Mitomycin C {0.4µM MMC}), excipient mixture 
(0.1 %) (EM), MYR B (10 µM) and MYR N (20 µM). (ns=not significant,*** P< 0.0001, ** P< 
0.001,* P< 0.01, * P< 0.04, *P<0.05).). 
Myricetin activates the P53 signalling pathway independent of DNA 
damage in lymphocytes 
Based on our previous results from the Comet and micronucleus assays we 
established that MYR B (10 µМ) and MYR N (20 µМ) have shown anti-
genotoxic effects in lymphocytes from healthy individuals and pre-cancerous 
patients. MYR N (20 µМ) exhibited genoprotective effects in lymphocytes from 
pre-cancerous patients by significantly reducing the MNi induction in MoNC. To 
identify the molecular mechanisms involved in this effect, we studied the 
influences of MYR B and MYR N on the gene expression levels of P53, a 
tumour-suppressor multi-functional gene in patients versus healthy 
lymphocytes. The tumour-suppressor P53 gene encodes for proteins that 
prevent genome mutations by interacting with DNA and regulating gene 
expression. Thus, it plays a significant role in prevention of carcinogenesis. This 
is why we studied P53 at the gene level. Total RNA was isolated from 
lymphocytes pre-treated with both forms of myricetin and subjected to 
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quantitative real-time PCR analysis. The results (Figure 5) have shown that 
myricetin nanoparticles significantly up-regulated the gene expression of P53 in 
patient lymphocytes compared to those from healthy individuals. This indicates 
that the protective effects caused by myricetin might be dependent on the 
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Figure 5. The influence of MYR B and MYR N, on the expression of P53 mRNA in 
lymphocyte from healthy individuals and pre-cancerous patients. GAPDH was used as an 
internal control   gene. Gene expression analysis was performed on lymphocytes after 24-hour 
treatment. P53 mRNA expression was significantly increased in lymphocyte from pre-cancerous 
patients after exposure to MYR N. Values are the means ± standard errors (SE)  of three 
independent experiments.. The p values are **p=0.008, ns=not significant. All values were 
compared against the respective control (C) and normalised against the GAPDH reference 
gene. 
Analysis of p53 protein expression in lymphocytes 
P53 plays a vital role in regulation of various cellular outcomes and responses 
such as angiogenesis, cell cycle arrest in the presence of DNA damage, DNA 
repair, apoptosis and transcription (Shaw, 1996; Haupt and Haupt, 2017). As 
cell cycle arrest and DNA repair are essential processes to protect cells against 
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further DNA damage and pre-existing damage, we investigated the effects of 
myricetin nanoparticles and bulk forms on P53 protein expression in the 
lymphocytes from pre-cancerous patients compared to those from healthy 
subjects. We carried out the Western blot procedure and analysed protein 
expression in lymphocytes from three healthy and three pre-cancerous patient 
samples. The results obtained were consistent with our PCR data. P53 protein 
expression is significantly increased by 2.3-fold (P<0.0001) with MYR B 
(P<0.0001)) and 2.0-fold with MYR N treatment in healthy lymphocytes (Figure 
6 A, B). Also, p53 showed a 1.3-fold increase in the lymphocytes of pre-
cancerous patients treated with MYR B, a 1.4-fold-increase (P=0.0140) after 
treatment with MYR N (P=0.0036). 
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Figure 6. Myricetin Bulk and nanoparticles significantly up-regulate the P53 protein levels 
in lymphocytes from pre-cancerous patients and healthy individuals(A) Immunoblot 
analysis of the p53 protein in lymphocyte treated with MYR B and MYR N. P53 expression was 
increased to 2.3-fold by MYR B and 2-fold by MYR N in the healthy group. In pre-cancerous 
patient MYR B induced 1.3-fold increase and MYR N treatment caused 1.4-fold increase in P53 
expression.  GAPDH was used as an internal control protein to normalise the data. (B) Bar 
graphs exhibiting fold changes in protein expression levels. Data are represented as the mean ± 
SE of three experiments. ***P<0.0001, **P=0.0036, *P=0.0140 
Discussion 
The current in vitro study investigated the effect of myricetin bulk and nano 
forms on human lymphocytes from patients with the pre-cancerous condition of 
MGUS and those from healthy individuals. 
Research has shown that myricetin inhibits the growth of human promyelocytic 
leukaemia (HL-60) cells by induction of apoptosis (Hibasami et al., 2005). It also 
decreases the viability of HL-60 cells via apoptosis through a ROS independent 
and mitochondria dependent pathway (Ko et al., 2005) and  induces pancreatic 
cell death in vitro (Phillips et al., 2011). Research has also indicated that 
myricetin is a strong inhibitor of the prostate cancer cell line PC-3 (Xu, 2013). 
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However, none of the previous studies have tested in vitro, the effect of 
myricetin bulk and nano forms on the DNA of human lymphocytes from pre-
cancerous patients. Genetically compromised DNA repair mechanisms might 
contribute to high levels of DNA damage in lymphocytes (Hanahan and 
Weinberg, 2000; Hanahan and Weinberg, 2011) therefore; lymphocytes are 
chosen as model cells for the current study. Peripheral lymphocytes represent 
an excellent model for examining the genome sensitivity (a factor of 
susceptibility to cancer) (Collins, 2004). If other somatic cell types are not 
accessible then lymphocytes can be used as surrogate cells to investigate the 
DNA damage and lymphocytes circulate in the blood stream across the body 
hence; are vulnerable to both endogenous and exogenous DNA damage by 
physio-chemical genotoxic insults (Najafzadeh et al., 2009). The alkaline Comet 
assay has been used to assess the DNA damage in lymphocytes from 
leukaemia patients (Collins, 2009). It has been proven a reliable method to 
assess the genotoxicity of NPs (Azqueta and Dusinska 2015). 
The Comet assay results from our study showed that exposing lymphocytes 
from healthy individuals and pre-cancerous patients to myricetin nano and bulk 
at lower concentrations (20 µM and 10 µM, respectively) did not induce any 
significant DNA damage when compared to their respective negative control 
groups (Akhtar et al., 2020 and Figure 3). The non-genotoxic behaviour of MYR 
B (10 µМ) and MYR N (20µМ) determined in this research is consistent with an 
earlier study which has shown that myricetin is a non-toxic and anti -mutagenic 
flavonoid (Wang, 2010). However, myricetin has induced dose dependent 
genotoxicity at higher concentrations. This might be possible due to the fact that 
flavonoids can potentially exhibit diverse effects at slightly different 
concentrations depending on the stimulus and the environment they interact 
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with or due to genotoxic artefacts which can occur at toxic doses. Therefore, we 
only used non-cytotoxic and non-genotoxic concentrations of both forms of 
myricetin to avoid such artefacts. 
The cytokinesis-block micronucleus assay, a test, to determine the capability of 
genotoxic substance to induce aneugenic and clastogenic effects on cell cycle 
and cellular division (Fenech, 2002) was used in the present study, for the first 
time to investigate the effects of myricetin bulk and nano forms on lymphocytes, 
particularly from pre-cancerous patients. The sensitivity of the assay is 
enhanced by cytochalasin B to block the cytokinesis, but not the mitosis, to 
facilitate binucleated cell accumulation. The MN in binucleated cells only shows 
the damage caused after the treatment and reduces the probability of scoring 
the pre-existing damage (Magdelenova et al., 2012). Mitomycin C (MMC), 
known as a clastogen, genotoxic and anti-cancerous agent, was used as a 
positive control as it has already been used in our laboratory as a positive 
control and it worked as expected by inducing MNi typically in binucleated cells 
rather than mononucleated (Elhajouji et al., 1998). Lower mean NDI and lower 
mononucleated cells were observed by treatment with MMC, which is consistent 
with previous studies performed at this lab (Najefzadeh, 2012).  
Evaluation of the assay showed that the frequency of MNi in MoNC from pre-
cancerous patients significantly decreased (Figure 4) when treated with MYR N 
(20 µM) but not with MYR B (10 µM), compared to the untreated control group. 
This clearly indicates that MYR N (20 µM) has significantly reduced the pre-
existing damage in MGUS patients at basal levels. This may be possibly due to 
either van der Waals forces or electrostatic interaction of NPs with nuclear 
proteins, for example repair proteins and facilitated repair (Magdelonova, 2012). 
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The double concentration of MYR N could also contribute towards its effective 
behaviour compared to MYR B. It could also be due to apoptosis induction 
through P53 up-regulation. In addition, the potential explanation for this is that 
NPs due to their very small size can easily reach the nucleus through diffusion 
across the nuclear membrane or transportation via the nuclear pores and gain 
direct interaction with the DNA (Magdolenova et al., 2014). Myricetin in both 
forms did not induce any nuclear bridges or buds. There were few MNi in MoNC 
seen in the treatment of healthy lymphocytes which indicates little pre-existing 
DNA damage due to lifestyle factors or any other medical procedure carried out.  
However, this number was raised in pre-cancerous patients due to increased 
levels of basal damage.  
Several studies have focused on understanding the cellular mechanisms 
involved in controlling the cell cycle changes, in reaction to DNA damage 
(Kuerbitx et al., 1992).   The critical molecular role played by P53 in DNA 
damage induced-cell cycle arrest is well distinct (Kastan et al., 1991). 
Increasing the amount of P53, cellular proliferation of tumour cells may be 
suppressed through DNA repair, cell cycle arrest and apoptosis. This could be 
another strategy for treating and preventing cancer development.   Our results 
demonstrate that 24-hour treatment with both the nanoparticles and bulk forms 
of myricetin activates the p53 protein at the post-translational level (Figure 6), 
suggesting that myricetin may ensure P53-dependent action—for instance 
acting as a tumour suppressor may arrest the G 1 phase of cell cycle, inhibiting 




Our results from the Comet and micronucleus assays showed that MYR B (10 
µМ) and MYR N (20 µМ) did not induce significant DNA damage in the 
lymphocytes from healthy individuals and pre-cancerous patients. However, 
both forms of myricetin induced concentration dependent effects at higher 
concentrations. MYR N (20 µМ) has shown genoprotective effects in 
lymphocytes from pre-cancerous patients by significantly inhibiting MNi 
induction in MoNC. These findings suggest that MYR B and MYR N can 
potentially exhibit both genotoxic and anti-genotoxic properties depending on 
the concentration, the stimulus applied and the substrate. However, at non-
genotoxic concentrations, myricetin could protect the lymphocytes of healthy 
individuals and pre-cancerous patients against DNA damage and possibly 
facilitate repair through a P53-mediated pathway. This suggests a possible role 
for myricetin at the right dose as a nutritional supplement for delaying the 
progression of the pre-cancerous condition of MGUS towards malignancy 
through its genoprotective property, primarily by interrupting phase 1 enzyme 
cytochrome (CYP) P450 (Batra and Sharma, 2013.  
Most flavonoids rarely reach 1 µМ concentration in our plasma when the 
amount of polyphenols does not exceed what is normally consumed in our 
varying diet.  This concentration is usually achieved within 1-2 hours of 
ingestion except for those which are partially degraded by the clonal microflora. 
After elimination of a half-life period (i.e. 1-2 hours normally) plasma 
concentration drops rapidly (Batra and Sharma, 2013). Thus, for the 
maintenance of the plasma concentrations of myricetin like other flavonoids, 
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